{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464392196
| IUPAC_name = 7-[(4''S'')-4-Amino-6-azaspiro[2.4]heptan-6-yl]-8-chloro-6-fluoro-1-[(2''S'')-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid
| image = sitafloxacin.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 127254-12-0
| ATC_prefix = J01
| ATC_suffix = MA21
| ATC_supplemental =  
| PubChem = 461399
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 405945
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 3GJC60U4Q8
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 108821
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D02475

<!--Chemical data-->
| chemical_formula =  
| C=19 | H=18 | Cl=1 | F=2 | N=3 | O=3 
| molecular_weight = 409.81
| smiles = F[C@H]5C[C@H]5N2/C=C(/C(=O)O)C(=O)c1cc(F)c(c(Cl)c12)N4C[C@@H](N)C3(CC3)C4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H18ClF2N3O3/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28)/t10-,12+,13+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PNUZDKCDAWUEGK-CYZMBNFOSA-N
}}

'''Sitafloxacin''' ([[International Nonproprietary Name|INN]]; also called '''DU-6859a''') is a [[fluoroquinolone]] antibiotic<ref>{{Cite journal | last1 = Anderson | first1 = DL. | title = Sitafloxacin hydrate for bacterial infections. | journal = Drugs Today (Barc) | volume = 44 | issue = 7 | pages = 489–501 |date=Jul 2008 | doi = 10.1358/dot.2008.44.7.1219561 | PMID = 18806900 }}</ref> that shows promise in the treatment of [[Buruli ulcer]]. The molecule was identified by [[Daiichi Sankyo Co.]], which brought [[ofloxacin]] and [[levofloxacin]] to the market.  Sitafloxacin is currently marketed in [[Japan]] by Daiichi Sankyo under the tradename '''Gracevit'''.

==See also==
*[[Quinolone antibiotic|Quinolone]]

==References==
{{reflist}}

==Further reading==
*{{cite journal |author=Keating GM |title=Sitafloxacin: in bacterial infections |journal=Drugs |volume=71 |issue=6 |pages=731–44 |date=April 2011 |pmid=21504249 |doi=10.2165/11207380-000000000-00000}}

==External links==
* {{ja icon}} [https://www.daiichisankyo.co.jp/med/contents/di/grv/pi/pdf/pi_grv_0806.pdf Gracevit グレースビット] (PDF) Daiichi Sankyo Co. January 2008.

{{QuinoloneAntiBiotics}}

{{antibiotic-stub}}

[[Category:Fluoroquinolone antibiotics]]
[[Category:Chloroarenes]]
[[Category:Cyclopropanes]]
[[Category:Organofluorides]]